| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 30.58% | Barrington Research | → $24 | Upgrades | Market Perform → Outperform |
| 08/10/2023 | 25.14% | Stephens & Co. | $28 → $23 | Maintains | Equal-Weight |
| 05/31/2023 | 52.34% | Stephens & Co. | → $28 | Reiterates | Equal-Weight → Equal-Weight |
| 04/14/2023 | 52.34% | Stephens & Co. | → $28 | Reiterates | → Equal-Weight |
| 03/07/2023 | — | Barrington Research | Downgrades | Outperform → Market Perform | |
| 11/09/2022 | 68.66% | Barrington Research | → $31 | Upgrades | Market Perform → Outperform |
| 10/14/2022 | 41.46% | Stephens & Co. | → $26 | Reinstates | → Equal-Weight |
| 03/09/2022 | — | Stephens & Co. | Downgrades | Overweight → Equal-Weight | |
| 11/16/2021 | 199.24% | Stephens & Co. | → $55 | Initiates Coverage On | → Overweight |
| 07/16/2021 | 150.27% | UBS | → $46 | Initiates Coverage On | → Neutral |
| 12/16/2020 | 133.95% | Barrington Research | → $43 | Upgrades | Market Perform → Outperform |
| 01/21/2020 | 231.88% | Sidoti & Co. | → $61 | Upgrades | Neutral → Buy |
| 11/05/2019 | 57.78% | BWS Financial | → $29 | Initiates Coverage On | → Sell |
| 09/23/2019 | — | First Analysis | Downgrades | Strong Buy → Outperform | |
| 02/22/2019 | 123.07% | Sidoti & Co. | $56 → $41 | Downgrades | Buy → Neutral |
What is the target price for Anika Therapeutics (ANIK)?
The latest price target for Anika Therapeutics (NASDAQ: ANIK) was reported by Barrington Research on August 14, 2023. The analyst firm set a price target for $24.00 expecting ANIK to rise to within 12 months (a possible 30.58% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Anika Therapeutics (ANIK)?
The latest analyst rating for Anika Therapeutics (NASDAQ: ANIK) was provided by Barrington Research, and Anika Therapeutics upgraded their outperform rating.
When is the next analyst rating going to be posted or updated for Anika Therapeutics (ANIK)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anika Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anika Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
Is the Analyst Rating Anika Therapeutics (ANIK) correct?
While ratings are subjective and will change, the latest Anika Therapeutics (ANIK) rating was a upgraded with a price target of $0.00 to $24.00. The current price Anika Therapeutics (ANIK) is trading at is $18.38, which is within the analyst's predicted range.